Wockhardt is currently trading at Rs. 697.30, up by 7.15 points or 1.04% from its previous closing of Rs. 690.15 on the BSE.
The scrip opened at Rs. 705.10 and has touched a high and low of Rs. 722.90 and Rs. 695.50 respectively. So far 389907 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1654.00 on 18-Dec-2015 and a 52 week low of Rs. 659.00 on 23-Nov-2016.
Last one week high and low of the scrip stood at Rs. 722.90 and Rs. 682.50 respectively. The current market cap of the company is Rs. 7787.00 crore.
The promoters holding in the company stood at 74.26%, while institutions and non-institutions held 8.73% and 16.98% respectively.
UK health regulator -- UK Medicines and Healthcare Products Regulatory Agency (UK MHRA) – has continued the approval status of Wockhardt’s manufacturing unit at Kadaiya, Daman relating to the principles and guidelines of Good Manufacturing Practices (GMP). The said manufacturing unit complies with the principles and guidelines which has now been continued by UK MHRA.
Last month, the company’s step down subsidiary - CP Pharmaceuticals, Wrexham, United Kingdom, had been issued a Warning Letter by the US Food and Drug Administration (USFDA).
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |